Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCS
At the San Antonio Breast Cancer Symposium (SABCS), an update of the phase III monarchE trial showed an…
Browsing Tag
SABCS
New Developments in HER2-Positive Breast Cancer at SABCS 2022
In this exclusive roundtable video from MedPage Today, three expert leaders in the field of breast cancer…
SABCS Trials Show Improved Outcomes in Metastatic Breast Cancer
In this exclusive MedPage Today video, Debu Tripathy, MD, chairman of the Department of Breast Medical…
What the SABCS ‘Year in Review’ Session May Bring in 2023
Each year, the San Antonio Breast Cancer Symposium (SABCS) concludes with the always-popular "Year in…
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast…
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal…
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual…
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the…
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows…
Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer…
Longest Follow-Up Data on Trastuzumab Biosimilar Presented at 2021 SABCS
Five-year follow-up results reconfirm comparable long-term efficacy of SB3 (ONTRUZANT®, trastuzumab-dttb) versus Herceptin® through additional analysis with a larger group of patients with…
Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus…
Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with…
Athenex 將在 SABCS 2021 上發表口服紫杉醇加 Encequidar (KX-ORAX-001) 用於治療轉移性乳癌的第 3 期研究的亞組分析
安全性數據分析表明，肝功能檢查升高的患者發生中性粒細胞減少相關毒性的風險增加 對該肝損傷患者亞組進行了事後分析，結果顯示口服紫杉醇治療的患者中位存活率為 18.9 個月，而靜脈注射紫杉醇治療的患者為 10.1 個月，風險比為 0.59 總存活期的增加抵消了中性粒細胞減少相關毒性併發症的風險 美國紐約州水牛城, Nov. 22, 2021 (GLOBE…